Entomologists review pros, cons and regulatory issues surrounding new technology that could help halt the spread of diseases such as Zika virus, dengue fever and malaria
Engineered gene drives, which have the potential to spread desirable genes throughout wild populations or to suppress harmful species, have received a lot of recent attention because of their potential to control organisms, such as mosquitoes that carry diseases such as Zika virus, malaria and dengue fever.
At the same time, the recently discovered CRISPR gene editing technology has the potential to create, streamline and improve the development of gene drives.
In a highly innovative and technical review, an entomologist at the University of California, Riverside has examined the different gene drives systems, analyzed the pros and cons of each and applications associated with them, and also surveyed the safety and regulatory issues associated with them.
“Despite all the potential benefits of gene drives, they remain understudied,” said Omar Akbari, an assistant professor of entomology at UC Riverside. “With that in mind, and with advances occurring so quickly, we wanted to step back and take a broad look at what is happening.”
Akbari, who is also a member of UC Riverside’s Center for Disease Vector Research andInstitute for Integrative Genome Biology, is the corresponding author of the piece, “Cheating evolution: engineering gene drives to manipulate the fate of wild populations,” that was just published online in the journal Nature Reviews Genetics. The piece was co-authored by Jackson Champer and Anna Buchman, both post-doctoral students working with Akbari.
The idea of editing the genes of organisms to address biological problems related to public and environmental health has been around for decades. In fact, the authors cite a paper from 1940 and others from the late 1960s that discuss this.
Despite the wide-ranging applicability and importance of gene drives, there has been only modest development in their progress in past decades. Gene drives capable of functioning in wild populations have been created in only a few organisms, including yeast, the fruitfly and two species of mosquitoes.
This is, in part, due to the difficulty of engineering the genomes of organisms. However, recent advancements have provided tools capable of engineering the genomes of diverse species. The most promising of these tools is CRISPR.
Combining gene drives and a tool such as CRISPR may enable the development of novel strategies to reduce or eliminate insect-borne diseases, remove invasive foreign species, and even reverse the development of resistance to insecticides and herbicides, in an economically viable and environmentally friendly manner.
In the paper, the authors focus on several types of gene drives, including homing-based drives, sex-linked meiotic drives, medea and underdominance gene drives. They describe the gene drives based on different attributes, including rate of spread, species specificity, fitness cost, susceptibility to resistance,removability and reversibility.
They also discuss whether the gene drives are classified as ‘modification drive’ types, which are designed to spread through a population carrying desirable traits, or as ‘suppression drive’ types, which have the effect of reducing the population of a target species.
Finally, the authors address safety and regulation. They mention dangers associated with gene drives, including the potential to cause extinctions, to spread outside a geographical area or traverse into another species and the potential misuse to cause economic damage or even bioterrorism.
Learn more: Engineered Gene Drives and the Future
The Latest on: Engineered gene drives
[google_news title=”” keyword=”engineered gene drives” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Engineered gene drives
- Common antibiotic Neosporin may shield against viral respiratory infectionson April 26, 2024 at 9:00 am
A study conducted first in mice and then in human volunteers suggests that a common antibiotic, neomycin, which is the main active ingredient in Neosporin, may help protect against viral respiratory ...
- 5 Lessons on Longevity From 5 Days With Blue Zones Founder Dan Buettner in Costa Ricaon April 26, 2024 at 6:00 am
T he Blue Zones are having a moment. Although bestselling author and former National Geographic journalist Dan Buettner coined the term back in 2004 to describe the places around the world where ...
- Buy Rating on Carisma Therapeutics: Pioneering CAR-M Therapies in Oncology and Fibrosison April 23, 2024 at 11:25 am
Analyst Naureen Quibria of Capital One Financial reiterated a Buy rating on Carisma Therapeutics (CARM – Research Report), retaining the ...
- Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meetingon April 22, 2024 at 1:30 pm
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s ...
- Cell Therapies Now Beat Back Once Untreatable Blood Cancers. Scientists Are Making Them Even Deadlier.on April 19, 2024 at 11:19 am
Two teams discovered a way to make cancer-fighting CAR T therapies even more effective—give engineered cells a protein boost to increase their longevity.
- Ginkgo to fold AgBiome microbial strain library into its West Sacramento AgBio centeron April 16, 2024 at 8:47 am
Ginkgo Bioworks said it will combine genetic assets it acquired from AgBiome into its biologics center in 200,000 square feet in West Sacramento.
- Elon Musk's FSD Is The End Of Manual Driving? Tesla Bull Gene Munster Believes 'Somebody Born Today Is Probably Never Going To Drive A Car'on April 15, 2024 at 8:20 pm
Tesla has decided to reduce the price of its 'full self-driving' subscription by half to $99 per month. This decision has led Gene Munster, Managing Partner at Deepwater Asset Management, to predict ...
- Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officeron April 15, 2024 at 5:00 am
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, ...
- Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)on April 15, 2024 at 4:27 am
Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE ---- Discovery ...
- Targeted new approach and computational tools reveal lung cancer subtypes hiding in patterns in cell-free DNAon April 10, 2024 at 11:00 am
Fred Hutch experts in small cell lung cancer and computational biology teamed up to develop an innovative approach that can distinguish between SCLC subtypes using big-picture patterns in cell-free ...
via Bing News